Objectives: To evaluate the efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC).
Methods: We analyzed data from a cohort of patients with advanced HCC treated using systemic treatment according to the local institutional protocol. Patients were divided into two groups, Group A, individuals <70 years of age, and Group B, individuals 70 years of age or older at the time of treatment initiation. Efficacy, measured based on overall survival (OS) and time to treatment failure (TTF), and toxicity were compared between groups.
Results: A total of 238 patients with advanced HCC who received sorafenib between 2007 and 2018 were evaluated. The median age for Group A was 59.1 years and that for Group B 73.6 years. The major prognostic characteristics were balanced between the groups. There were no significant differences in OS between Group A (8.0 months, 95%CI 6.34-9.3) and Group B (9.0 months, 95%CI 5.38-12.62), p=0.433, or in TTF between Group A (3.0 months, 95%CI 2.39-3.60) and Group B (3.0 months, 95%CI 1.68-4.32), p=0.936. There were no significant differences between Groups A and B with respect to the incidence of adverse events or treatment discontinuation because of toxicity.
Conclusion: Efficacy and safety of sorafenib did not differ significantly between younger and older patients with HCC. Our data suggest that age alone should not restrict clinical decision-making for patients with advanced HCC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811833 | PMC |
| http://dx.doi.org/10.6061/clinics/2021/e2498 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Significance of Bone Metastases in Pleural Mesothelioma.
Thorac Cancer
March 2025
Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Background: Bone metastasis (BoM) is common in advanced cancer, but its incidence in pleural mesothelioma (PM) remains unclear. This study aimed to determine the incidence of BoM in PM patients and assess its prognosis and risk factors to clarify its clinical significance.
Methods: A retrospective analysis was conducted on 515 histologically confirmed PM patients enrolled between January 2011 and December 2020.
ChatGPT and other artificial intelligence (AI) tools can modify nutritional management in clinical settings. These technologies, based on machine learning and deep learning, enable the identification of risks, the proposal of personalized interventions, and the monitoring of patient progress using data extracted from clinical records. ChatGPT excels in areas such as nutritional assessment by calculating caloric needs and suggesting nutrient-rich foods, and in diagnosis, by identifying nutritional issues with technical terminology.
View Article and Find Full Text PDFMinimal important change for the aphasia quotient of the Chinese Western Aphasia Battery.
Eur J Phys Rehabil Med
March 2025
Department of Rehabilitation Medicine, Huashan Hospital, Fudan University, Shanghai, China -
Background: There is limited research on the Minimal Important Change (MIC) of the Chinese Western Aphasia Battery (WAB). Since an MIC for Chinese WAB has yet to be established, the clinical implications of data using the Chinese WAB remain unclear.
Aim: This study was to establish the MIC of the Aphasia Quotient (AQ) of the Chinese WAB.
Background: The development of immunotherapy has led to a paradigm shift in the treatment of malignant tumors. Immune checkpoint inhibitors (ICIs) function by blocking the receptors and ligands of T cells from binding one another, empowering them to target and attack cancer cells. ICIs along with other immunotherapy treatments, have seen a significant increase in usage in recent years.
View Article and Find Full Text PDFWho cares about the dying? - Unpacking integration of palliative care and oncology in the Danish context.
Health Sociol Rev
March 2025
Department of Health, VIVE - The Danish Center for Social Science Research, Copenhagen, Denmark.
Integrating palliative care into the trajectories of patients with incurable cancer has been a priority for years. Yet, the intended outcomes of this integration remain elusive. Many patients with advanced cancer continue to receive so-called aggressive treatments in the end-of-life phase or miss out on specialised palliative care entirely.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!